Tetratherix Reports Positive Tendon-Repair Results for TegenEOS and PRP
TTX: $5.35 -2.73% · MC: $340M
Tetratherix says its ten-week preclinical study found better tendon healing with TegenEOS carrying platelet-rich plasma (PRP) than with PRP alone, including more organised blood vessels and less inflammation and scar-like tissue at six weeks. The results extend the potential use of TegenEOS, currently a bone-graft carrier, to delivering biologics for soft-tissue repair; the company says the approach is intended to keep PRP at the injury site as it sets into a gel at body temperature.

Comments